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We have recently demonstrated that osteopontin
(OPN) induces nuclear factor B (NFB)-mediated
promatrix metalloproteinase-2 activation through IB/
IB kinase (IKK) signaling pathways. However, the mo-
lecular mechanism(s) by which OPN regulates proma-
trix metalloproteinase-9 (pro-MMP-9) activation, MMP-
9-dependent cell motility, and tumor growth and the
involvement of upstream kinases in regulation of these
processes in murine melanoma cells are not well de-
fined. Here we report that OPN induced v3 integrin-
mediated phosphorylation and activation of nuclear fac-
tor-inducing kinase (NIK) and enhanced the interaction
between phosphorylated NIK and IKK/ in B16F10
cells. Moreover, NIK was involved in OPN-induced phos-
phorylations of MEK-1 and ERK1/2 in these cells. OPN
induced NIK-dependent NFB activation through ERK/
IKK/-mediated pathways. Furthermore OPN en-
hanced NIK-regulated urokinase-type plasminogen acti-
vator (uPA) secretion, uPA-dependent pro-MMP-9
activation, cell motility, and tumor growth. Wild type
NIK, IKK/, and ERK1/2 enhanced and kinase-negative
NIK (mut NIK), dominant negative IKK/ (dn IKK/),
and dn ERK1/2 suppressed the OPN-induced NFB acti-
vation, uPA secretion, pro-MMP-9 activation, cell motil-
ity, and chemoinvasion. Pretreatment of cells with anti-
MMP-2 antibody along with anti-MMP-9 antibody
drastically inhibited the OPN-induced cell migration
and chemoinvasion, whereas cells pretreated with anti-
MMP-2 antibody had no effect on OPN-induced pro-
MMP-9 activation suggesting that OPN induces pro-
MMP-2 and pro-MMP-9 activations through two distinct
pathways. The level of active MMP-9 in the OPN-in-
duced tumor was higher compared with control. To our
knowledge, this is the first report that NIK plays a cru-
cial role in OPN-induced NFB activation, uPA secre-
tion, and pro-MMP-9 activation through MAPK/IKK/-
mediated pathways, and all of these ultimately control
the cell motility, invasiveness, and tumor growth.
Osteopontin (OPN)1 is a secreted, non-collagenous, sialic
acid-rich phosphoglycoprotein (1, 2). OPN acts both as che-
mokine and cytokine. It has an N-terminal signal sequence, a
highly acidic region consisting of nine consecutive aspartic
acid residues, and a GRGDS cell adhesion sequence predicted
to be flanked by the -sheet structure (3). This protein has a
functional thrombin cleavage site and is the substrate for
tissue transglutaminase (2). It is produced by osteoclast,
macrophages, T cells, hematopoietic cells, and vascular
smooth muscle cells (4). OPN binds with type I collagen (5),
fibronectin (6), and osteocalcin (7). Several highly metastatic
transformed cells synthesize higher levels of OPN compared
with non-tumorigenic cells (8). It has been shown that OPN
also interacts with several integrins and CD44 variants in an
RGD sequence-dependent and -independent manner (9, 10).
OPN is involved in normal tissue remodeling processes such
as bone resorption, angiogenesis, wound healing, and tissue
injuries as well as certain diseases such as restenosis, ath-
erosclerosis, tumorigenesis, and autoimmune diseases (10–
12). OPN causes cell adhesion, migration, extracellular ma-
trix (ECM) invasion, and cell proliferation by interaction with
its receptor v3 integrin in various cell types (10). Integrins
are noncovalently associated, heterodimeric, cell surface gly-
coproteins with - and -subunits.
The NFB family consists of several members including p65,
p50, Rel B, and c-Rel molecules (13). The activity of NFB is
tightly regulated by its inhibitors, the IB family of proteins
(14). These inhibitory proteins bind to NFB dimers, masking
their nuclear localization sequence resulting in cytoplasmic
retention of NFB (15). Upon stimulation, IB is phosphoryl-
ated and degraded via the ubiquitination and proteosome-me-
diated pathway leading to the nuclear import of NFB where it
binds to cognate sequence in promoter regions of multiple
genes. IB kinase (IKK) is a multisubunit protein kinase, the
activation of which phosphorylates IB. Nuclear factor-induc-
ing kinase (NIK) is a member of the mitogen-activated protein
kinase kinase kinase family that may either directly or indi-
rectly phosphorylate or activate IKK/, leading to the phos-
phorylation and degradation of IB followed by NFB activa-
tion (16). Previous data also has indicated that NIK regulates
differentiation of PC-12 cells through phosphorylation and ac-
tivation of MEK-1 (17). The data also show that constitutively
expressed or overexpressed wild type NIK in the presence of
TNF, interleukin-1, TRAF-2, and TRAF-6 induced, and kinase-
negative NIK (mut NIK) in the presence of the same stimuli
suppressed, the NFB activation (18, 19). Our previous results
indicate that OPN induces cell motility, tumor growth, NFB-
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mediated urokinase-type plasminogen activator (uPA) secre-
tion, and promatrix metalloproteinase-2 (pro-MMP-2) activa-
tion through the phosphatidylinositol 3-kinase/IKK/Akt
signaling pathways (20–22). However, the signaling pathway
by which OPN regulates NIK activation and NIK-dependent
MAPK/IKK-mediated NFB activation through phosphoryla-
tion and degradation of IB in B16F10 cells is not well
defined.
uPA is a serine protease that interacts with uPA receptor
and facilitates the conversion of inert zymogen plasminogen
into widely acting serine protease plasmin and activation of
MMPs (23, 24). These proteases then degrade the surround-
ing matrix components (collagen, gelatin, fibronectin, and
laminin) and allow cancer cells to migrate to distant sites. It
is established that uPA plays a significant role in tumor
growth and metastasis (25, 26). NFB-response element is
present in the promoter region of uPA, which plays a key role
in cancer metastasis. However, the molecular mechanism by
which OPN regulates NIK activation and NIK-dependent
MAPK- and IKK-mediated NFB activation and uPA secre-
tion, which lead to the activation of pro-MMP-9 and control
cell migration, ECM invasion, and tumor growth, is not well
documented.
MMPs are ECM-degrading enzymes that play a critical role
in embryogenesis, tissue remodeling, inflammation, and angio-
genesis (27). We have recently reported that OPN induces
NFB-mediated pro-MMP-2 activation through IB/IKK sig-
naling pathways (20, 21). MMP-9 (also called type IV collagen-
ase or gelatinase B) is another important contributor to the
process of invasion, tumor growth, and metastasis (28–31).
MMP-9 can efficiently degrade native type IV and V collagens,
fibronectin, ectactin, and elastin. The regulation of activation
of MMP-9 is more complex than that of most of the other MMPs
because most of the cells do not express a constitutively active
form of MMP-9, but its activity is induced by different stimuli
depending on cell types (32–34) thereby contributing to the
specific pathological events. MMP-9 is not only associated with
invasion and metastasis but also has been implicated in angio-
genesis, rheumatoid arthritis, retinopathy, and vascular steno-
sis, and hence MMP-9 is considered to be a therapeutic target
of high priority (35). Earlier reports indicate that transgenic
mice lacking MMP-9 show reduced keratinocyte hyperprolif-
eration and decreased incidence of invasive tumors (36). NFB-
responsive element is present in the promoter region of
MMP-9, which plays a key role in cancer metastasis. However,
the molecular mechanism by which OPN regulates NFB-me-
diated pro-MMP-9 activation and controls cell migration and
tumor growth is not well understood.
In this study, we found that OPN induced phosphorylation
and activation of NIK and the interaction between phosphoryl-
ated NIK and IKK in B16F10 cells. OPN enhanced NIK- and
IKK-dependent NFB activation. OPN also induced NIK-me-
diated NFB activation by modulating the phosphorylation of
ERK1/2. Moreover OPN induced uPA secretion and uPA-de-
pendent pro-MMP-9 activation, cell motility, chemoinvasion,
and tumor growth. The OPN-induced NIK-dependent ERK/
IKK-mediated NFB transactivation, pro-MMP-9 activation,
and cell motility were enhanced when cells were transfected
with wild type NIK, IKK/, and ERK1/2 and suppressed when
cells were transfected with mut NIK, dn IKK/, or dn ERK1/2.
Taken together, these data demonstrated that OPN enhances
cell motility, chemoinvasion, and tumor growth and induces
NIK-dependent NFB-mediated uPA secretion and uPA-regu-
lated pro-MMP-9 activation through MAPK/IKK-mediated sig-
naling pathways.
EXPERIMENTAL PROCEDURES
Materials—The rabbit polyclonal anti-phospho-NIK (Thr-559), anti-
NIK, anti-IKK/, anti-NFB p65 X TransCruz, anti-p-MEK-1, anti-
MEK-1, anti-ERK1/2, anti-IB, anti-uPA, anti-MMP-9, and anti-actin
and the mouse monoclonal anti-phospho-ERK1/2, anti-phospho-IB
antibodies, and IB recombinant protein were purchased from Santa
Cruz Biotechnology. Mouse monoclonal anti-MMP-9 was from Onco-
gene. Mouse monoclonal anti-human v3 integrin antibody was from
Chemicon International. LipofectAMINE Plus, GRGDSP, and GRGESP
were obtained from Invitrogen. PD98059 was from Calbiochem. TNF
was from R&D Systems. The dual luciferase reporter assay system and
NFB consensus oligonucleotide were purchased from Promega. Boy-
den type cell migration chambers were obtained from Corning, and
BioCoat MatrigelTM invasion chambers were from Collaborative Bio-
medical. The [-32P]ATP was purchased from Board of Radiation and
Isotope Technology (Hyderabad, India). The human OPN was purified
from milk as described previously and used throughout these studies
(20). The nude mice (NMRI, nu/nu) were from National Institute of
Virology (Pune, India). All other chemicals were of analytical grade.
Cell Culture—The B16F10 cells were obtained from American Type
Culture Collection (Manassas, VA). These cells were cultured in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal calf
serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM
glutamine in a humidified atmosphere of 5% CO2 and 95% air at 37 °C.
Plasmids and DNA Transfection—The wild type NIK (wt pcDNA
NIK) and kinase-negative NIK (mut pcDNA NIK, NIK-K429A/K430A)
in pcDNA3 were generous gifts from Prof. David Wallach (Weizmann
Institute of Science, Rehovot, Israel). The wild type and dominant
negative constructs of IKK (wt IKK and dn IKK) and IKK (wt
IKK and dn IKK) in pRK were kind gifts from Prof. D. V. Goeddel
(Tularik Inc., San Francisco, CA). The wt ERK1 and dn ERK1 in pCEP4
and wt ERK2 and dn ERK2 in p3XFLAG-CMV-7.1 were from Dr.
Melanie Cobb (Department of Pharmacology, University of Texas
Southwestern Medical Center, Dallas, TX). The luciferase reporter con-
struct (pNFB-Luc) containing five tandem repeats of the NFB bind-
ing site was a generous gift from Dr. Rainer de Martin (University of
Vienna, Vienna, Austria). The super-repressor form of IB cDNA
fused downstream to a FLAG epitope in an expression vector (pCMV4)
was a gift from Dr. Dean Ballard (Vanderbilt University School of
Medicine, Nashville, TN). B16F10 cells were split 12 h prior to trans-
fection in Dulbecco’s modified Eagle’s medium containing 10% fetal calf
serum. These cells were transiently transfected with cDNA using Lipo-
fectAMINE Plus according to manufacturer’s instructions. Briefly
cDNA (8 g) was mixed with Plus reagent, and then the cDNA Reagent
Plus were incubated with LipofectAMINE. The LipofectAMINE Plus
cDNA complex was added to the cells and incubated further at 37 °C for
12 h. The control cells received LipofectAMINE Plus alone. The cell
viability was detected by a trypan blue dye exclusion test. After incu-
bation, the medium was removed, and the cells were refed with fresh
medium and maintained for an additional 12 h. These transfected cells
were used for interaction studies between phosphorylated NIK and
IKK, IB phosphorylation, IKK assay, MEK-1 and ERK1/2 phospho-
rylations, EMSA, NFB luciferase reporter gene assay, and detection of
MMP-9 by zymography and Western blot and uPA secretion by Western
blot, cell migration, and chemoinvasion assays.
In Vitro Kinase Assay—To examine the effect of OPN on NIK activ-
ity, the semiconfluent B16F10 cells were treated with 5 M OPN for 5
min at 37 °C. The cells were lysed in kinase assay lysis buffer (20 mM
Tris-HCl (pH 8.0), 500 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM
-glycerophosphate, 10 mM NaF, 10 mM p-nitrophenyl phosphate, 300
M Na3VO4, 1 mM benzamidine, 2 M phenylmethylsulfonyl fluoride, 10
g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 mM DTT, and
0.25% Nonidet P-40). The supernatant was obtained by centrifugation
at 12,000  g for 10 min at 4 °C. The cell lysates containing an equal
amount of total proteins were immunoprecipitated with rabbit anti-
NIK antibody. Half of the immunoprecipitated samples were incubated
with IKK as substrate in kinase assay buffer (20 mM Hepes (pH 7.7), 2
mM MgCl2, 10 mM -glycerophosphate, 10 mM NaF, 10 mM p-nitrophe-
nyl phosphate, 300 M Na3VO4, 1 mM benzamidine, 2 M phenylmeth-
ylsulfonyl fluoride, 10 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml
pepstatin, and 1 mM DTT) containing 10 M ATP and 3 Ci of
[-32P]ATP at 30 °C. The kinase reactions were stopped by addition of
SDS sample buffer. The samples were resolved by SDS-PAGE, dried,
and autoradiographed. The remaining half of the immunoprecipitated
samples were subjected to SDS-PAGE and analyzed by Western blot
using anti-NIK antibody. A fraction of equal volume of samples from the
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kinase reaction mixture was analyzed by Western blot using anti-
IKK/ antibody.
To investigate the role of NIK in OPN-induced IKK activity, the cells
were treated with 5 M OPN for 10 min at 37 °C. In separate experi-
ments, cells were transfected with wild type NIK or kinase-negative
NIK in the presence of LipofectAMINE Plus and then treated with 5 M
OPN. The cells were lysed in kinase assay lysis buffer. The cell lysates
containing an equal amount of total proteins (300 g) were immuno-
precipitated with anti-IKK/ antibody. Half of the immunoprecipi-
tated samples were incubated with recombinant IB (4 g) in kinase
buffer (20 mM Hepes (pH 7.7), 2 mM MgCl2, 10 M ATP, 3 Ci of
[-32P]ATP, 10 mM -glycerophosphate, 10 mM NaF, 10 mM p-nitrophe-
nyl phosphate, 300 M Na3VO4, 1 mM benzamidine, 2 M phenylmeth-
ylsulfonyl fluoride, 10 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml
pepstatin, and 1 mM DTT) at 30 °C. The kinase reaction was stopped by
addition of SDS sample buffer. The sample was resolved by SDS-PAGE,
dried, and autoradiographed. The remaining half of the immunoprecipi-
tated samples were analyzed by Western blot using anti-IKK/ anti-
body. A fraction of equal volume of samples from the kinase reaction
mixture was analyzed by Western blot using anti-IB antibody. The
level of NIK in the immunoprecipitated samples was analyzed by West-
ern blot using anti-NIK antibody.
To check whether OPN regulates the interaction between phospho-
rylated NIK and IKK/, cells were treated with 5 M OPN at 37 °C for
10 min. Cell lysates were immunoprecipitated with rabbit anti-IKK/
antibody. The immunoprecipitated samples were analyzed by Western
blot using rabbit anti-phospho-NIK antibody. The same blots were
reprobed with anti-IKK/ antibody as loading control.
Western Blot Analysis—To delineate the role of OPN in regulation of
NIK phosphorylation, the cells were treated with 5 M OPN for 0–30
min. In separate experiments, cells were pretreated with anti-v3
integrin antibody (20 g/ml) or GRGDSP or GRGESP peptide (10 M)
and then treated with 5 M OPN for 7 min at 37 °C. In other experi-
ments, cells were treated with TNF (20 ng/ml) for 5 min as positive
control. The cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1% Nonidet P-40, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 5 mM iodoacetamide, and 2 mM phenylmethylsulfo-
nyl fluoride), and the lysates containing an equal amount of total
proteins were analyzed by Western blot with rabbit anti-phospho-NIK
antibody. The same blots were reprobed with rabbit anti-NIK or anti-
actin antibody as loading controls and detected by the ECL detection
system (Amersham Biosciences).
To examine the effect of NIK on OPN-induced IB phosphorylation
and degradation, cells were transfected with either wild type NIK or
kinase-negative NIK and then treated with 5 M OPN for 10 min. The
cell lysates were analyzed by Western blot using mouse anti-phospho-
IB antibody. The same blots were reprobed with rabbit anti-IB
antibody. As loading control, the expression of actin was also detected
by reprobing the blot with anti-actin antibody.
To detect whether NIK regulates OPN-induced MEK-1 and ERK1/2
phosphorylations, cells were transfected with wild type or kinase-negative
NIK and then treated with 5 M OPN for 10 min. Cell lysates were
analyzed by Western blot using anti-p-MEK-1 or anti-p-ERK1/2 antibody.
The same blots were reprobed with anti-MEK-1 or anti-ERK1/2 antibody.
To check whether v3 integrin is involved in OPN-induced MEK-1
phosphorylation, the cells were pretreated with anti-v3 antibody or
RGD peptide (GRGDSP or GRGESP) and then treated with OPN. The
cell lysates were subjected to Western blot analysis using anti-p-MEK-1
antibody. The same blots were reprobed with anti-MEK-1 antibody.
To investigate the role of OPN on pro-MMP-9 activation, the cells
were treated with 5 M OPN for 24 h. In separate experiments, cells
were pretreated with anti-v3 integrin antibody (20 g/ml), RGD/RGE
peptide (10 M GRGDSP or GRGESP), anti-uPA antibody (25 g/ml), or
anti-MMP-2 antibody (0–50 g/ml) for 1 h and then treated with 5 M
OPN. The conditioned medium was collected, concentrated, and dia-
lyzed. The samples containing an equal amount of total proteins were
analyzed by Western blot using rabbit anti-MMP-9 antibody.
To ascertain the role of NIK in OPN-induced uPA secretion, the cells
were either treated with 0–5 M OPN or transfected with wild type NIK
or mut NIK and then treated with 5 M OPN for 24 h. To examine
whether ERK1/2 plays any roles in OPN-induced uPA secretion, cells
were transfected with wild type or dn ERK1/2 and then treated with
OPN. The cell lysates containing an equal amount of total proteins were
subjected to Western blot analysis using rabbit polyclonal anti-uPA
antibody. As loading controls the expression of actin was also detected
by reprobing the blots with rabbit anti-actin antibody.
Zymography Experiments—The gelatinolytic activity was measured
as described previously (20). To further check the effect of OPN on
pro-MMP-9 activation, the cells were treated with 0–10 M OPN for
24 h or pretreated with anti-uPA antibody (25 g/ml) for 1 h and then
treated with 5 M OPN. The conditioned medium was collected by
centrifugation. The samples containing an equal amount of total pro-
teins were mixed with sample buffer in the absence of reducing agent
and loaded onto zymography SDS-polyacrylamide gels containing gel-
atin (0.5 mg/ml) as described previously (20). The gels were incubated in
incubation buffer (50 mM Tris-HCl (pH 7.5) containing 100 mM CaCl2, 1
M ZnCl2, 1% (v/v) Triton X-100, and 0.02% (w/v) NaN3) for 16 h. The
gels were stained with Coomassie Blue and destained. Negative stain-
ing showed the zones of gelatinolytic activity. In another experiment,
cells were also transfected with wild type NIK, kinase-negative NIK, or
the super-repressor form of IB in the presence of LipofectAMINE
Plus and then treated with OPN for 24 h. In separate experiments, cells
were transfected with wild type or dominant negative IKK and IKK
and then treated with 5 M OPN. The conditioned medium was col-
lected, and the level of active MMP-9 was detected by zymography as
described above.
EMSA—To check whether NIK and IKK play any role in OPN-
induced NFB-DNA binding, cells were either treated with 5 M OPN
or transfected with wild type NIK, kinase-negative NIK, or wild type
and dn IKK and then treated with OPN for 6 h at 37 °C, and EMSA
was performed as described previously (37). To investigate whether
MEK-1 or ERK1/2 is involved in OPN-induced NFB-DNA binding and
whether it is regulated by NIK, cells were either pretreated with
PD98059 or transfected with wt NIK or kinase-negative NIK and then
treated with PD98059 or transfected with wild type and dn ERK1 and
ERK2. Transfected or treated cells were further treated with OPN. The
nuclear extracts were prepared as described earlier (37). Briefly the
cells were resuspended in hypotonic buffer (10 mM Hepes (pH 7.9), 1.5
mM MgCl2, 10 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5
mM dithiothreitol). The nuclear pellet was extracted in nuclear extrac-
tion buffer (20 mM Hepes (pH 7.9), 0.4 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 25% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, and 0.5 mM
DTT). The supernatant was used as a nuclear extract. The nuclear
extracts (10 g) were incubated with 16 fmol of 32P-labeled double-
stranded NFB oligonucleotide (5-AGT TGA GGG GAC TTT CCC AGG
C-3) in binding buffer (25 mM Hepes buffer (pH 7.9), 0.5 mM EDTA, 0.5
mM DTT, 1% Nonidet P-40, 5% glycerol, 50 mM NaCl) containing 2 g of
polydeoxyinosinic deoxycytidylic acid (poly(dI-dC)). The DNA-protein
complex was resolved on a native polyacrylamide gel and analyzed by
autoradiography. For supershift assay, the OPN-treated nuclear ex-
tracts were incubated with anti-NFB p65 (TransCruz) antibody for 30
min at room temperature and analyzed by EMSA.
NFB Luciferase Reporter Gene Assay—The semiconfluent cells
grown in 24-well plates were transiently transfected with a luciferase
reporter construct (pNFB-Luc) containing five tandem repeats of the
NFB binding site using LipofectAMINE Plus reagent (Invitrogen). In
separate experiments, cells were individually transfected with wild
type NIK, kinase-negative NIK, the super-repressor form of IB, wild
type and dn IKK and IKK, or wild type and dn ERK1 and ERK2
along with pNFB-Luc. The transfection efficiency was normalized by
cotransfecting the cells with pRL vector (Promega) containing a full-
length Renilla luciferase gene under the control of a constitutive pro-
moter. After 24 h of transfection, cells were treated with 5 M OPN for
6 h. Cells were harvested in passive lysis buffer (Promega). The lucif-
erase activities were measured by luminometer (Lab Systems) using
the dual luciferase assay system according to the manufacturer’s in-
structions (Promega). Changes in luciferase activity with respect to
control were calculated.
Cell Migration Assay—The migration assay was conducted using a
Transwell cell culture chamber according to the standard procedure as
described previously (20–22). Briefly the confluent monolayers of
B16F10 cells were harvested with trypsin-EDTA and centrifuged at
800  g for 10 min. The cell suspension (5  105cells/well) was added to
the upper chamber of the prehydrated polycarbonate membrane filter.
The lower chamber was filled with fibroblast-conditioned medium,
which acted as a chemoattractant. Purified OPN (5 M) was added to
the upper chamber. In another experiment, cells were individually
pretreated with PD98059 (0–50 M), anti-uPA antibody (25 g/ml),
anti-MMP-9 antibody (25 g/ml), anti-MMP-2 antibody (25 g/ml), or a
combination of anti-MMP-2 and anti-MMP-9 antibodies (25 g/ml) at
37 °C for 6 h. In other experiments, cells were individually transfected
with wild type and kinase-negative NIK, the super-repressor form of
IB, wild type and dn IKK and IKK, or wild type and dn ERK1 and
ERK2 and used for migration assays. These treated or transfected cells
were incubated in a humidified incubator in 5% CO2 and 95% air at
37 °C for 16 h. The non-migrated cells on the upper side of the filter
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were scraped, and the filter was washed. The migrated cells on the
reverse side of the filter were fixed with methanol and stained with
Giemsa. The migrated cells on the filter were counted under an inverted
microscope (Olympus). The experiments were repeated in triplicate.
Preimmune IgG served as a nonspecific control.
Chemoinvasion Assay—The chemoinvasion assay was performed us-
ing a Matrigel-coated invasion chamber as described previously (20–
22). The cell suspension (5  105 cells/well) was added to the upper
portion of the prehydrated Matrigel-coated chamber. The lower cham-
ber was filled with fibroblast-conditioned medium, which acted as a
chemoattractant. Purified OPN (5 M) was added to the upper chamber.
In another experiment, cells were individually pretreated with anti-
MMP-9 antibody (25 g/ml), anti-MMP-2 antibody (25 g/ml), a combi-
nation of anti-MMP-2 and anti-MMP-9 antibodies, and anti-uPA anti-
body (25 g/ml) at 37 °C for 6 h. In other experiments, cells were
individually transfected with wild type and kinase-negative NIK, wild
type and dn IKK and IKK, or the super-repressor form of IB as
described above and used for invasion assays. OPN (5 M) was used in
the upper chamber. The cells were incubated at 37 °C for 16 h. The
non-migrated cells and Matrigel from the upper side of the filter were
scraped and removed using a moist cotton swab. The invaded cells on
the lower side of the filter were stained with Giemsa and washed with
phosphate-buffered saline (pH 7.6). The invaded cells were then
counted, and photomicrographs were taken under the inverted micro-
scope (Olympus). The experiments were repeated in triplicate. Preim-
mune IgG served as a nonspecific control.
In Vivo Tumorigenicity Experiments—The tumorigenicity experi-
ments were performed as described previously (20, 21). The cells were
treated in the absence or presence of purified human OPN (10 M) at
37 °C for 20 h. After that, the cells (5  106/0.2 ml) were detached and
injected subcutaneously into the flanks of male athymic NMRI (nu/nu)
mice (6–8 weeks old). Four mice were used in each set of experiments.
The mice were kept under specific pathogen-free conditions. OPN (10
M) was again injected into the tumor sites twice a week for up to 4
weeks. After 4 weeks, the mice were killed, and the tumor weights were
measured. The tumor tissues were homogenized and lysed in lysis
buffer (50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 1% Nonidet
P-40, 15 g/ml leupeptin, and 0.5 mM phenylmethylsulfonyl fluoride)
and centrifuged at 12,000  g for 10 min. The clear supernatants were
collected, and the levels of pro- and active MMP-9 were detected by
Western blot analysis. Briefly the samples containing an equal amount
of total proteins were resolved by SDS-PAGE and analyzed by Western
blot using anti-MMP-9 antibody. The levels of pro- and active MMP-9 in
tumor samples were also analyzed by zymography as described above.
RESULTS
OPN Induces v3 Integrin-dependent NIK Phosphoryla-
tion—Because we have reported earlier that OPN induces
NFB-mediated pro-MMP-2 activation through IKK/IB-me-
diated pathway (20), we first examined whether any upstream
kinase(s) such as NIK plays any role in OPN-induced NFB
activation in B16F10 cells. Accordingly these cells were treated
with 5 M OPN for 0–30 min at 37 °C. The cell lysates contain-
ing an equal amount of total proteins were resolved by SDS-
PAGE, and the level of phosphorylated NIK was detected by
Western blot analysis using anti-phospho-NIK (Thr-559) anti-
body (Fig. 1, upper panel A, lanes 1–5). The data revealed that
the maximum level of OPN-induced NIK phosphorylation oc-
curred at 7 min (upper panel A, lane 3) and also suggested that
Thr-559 of NIK is crucial for OPN-induced NIK phosphoryla-
tion. The same blots were reprobed with anti-NIK antibody as
loading control, and the data showed that there was no change
in expression of non-phospho-NIK in these cells upon treat-
ment with OPN, confirming the equal loading of samples (mid-
dle panel A, lanes 1–5). Actin was also used as a loading control
(lower panel A, lanes 1–5). To further check whether v3
integrin or the RGD/RGE peptide is involved in OPN-induced
NIK phosphorylation, cells were pretreated with anti-v3 in-
FIG. 1. Panel A, OPN stimulates NIK phosphorylation. B16F10 cells were treated with 5 M OPN for 0–30 min. The cell lysates containing an
equal amount of total proteins were analyzed by Western blot using anti-phospho-NIK antibody (upper panel A, lanes 1–5). The blots were reprobed
with anti-NIK (middle panel A) or anti-actin antibody (lower panel A) as loading controls. Panel B, OPN induces NIK phosphorylation through v3
integrin-mediated pathways. The cells were individually pretreated with anti-v3 integrin antibody, GRGDSP, or GRGESP and then treated with
5 M OPN. The cell lysates were analyzed by Western blot using anti-phospho-NIK antibody (upper panel B, lanes 1–5). The same blots were
reprobed with anti-NIK antibody (lower panel B). Panel C, TNF, as control, enhances NIK phosphorylation. Cells were treated with TNF, and
levels of phospho- and non-phospho-NIK were detected by Western blot (panel C). Panel D, OPN induces the interaction between phosphorylated
NIK and IKK. The cells were treated with 5 M OPN. In separate experiments, cells were transfected with wt or kinase-negative NIK and then
treated with OPN. Cell lysates were immunoprecipitated with anti-IKK/ antibody. Half of the samples were immunoblotted with anti-phospho-
NIK antibody (upper panel D, lanes 1–4), and the other half were analyzed by anti-IKK/ antibody (lower panel D, lanes 1–4). All these bands
were analyzed densitometrically, and the -fold changes were calculated. The data shown here represent three experiments exhibiting similar
effects. IB, immunoblot; pNIK, phospho-NIK; IP, immunoprecipitation; Ab, antibody.
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tegrin antibody or RGD/RGE peptide (GRGDSP or GRGESP)
and then treated with OPN. The level of phosphorylated NIK
was detected by Western blot analysis. The data showed that
v3 integrin antibody and RGD (GRGDSP) but not RGE
(GRGESP) peptide suppressed the OPN-induced NIK phospho-
rylation in these cells (upper panel B, lanes 1–5). The level of
non-phospho-NIK was unchanged (lower panel B, lanes 1–5).
As a control, cells were treated with TNF, and the levels of
phosphorylated and non-phosphorylated NIK were detected by
Western blot using anti-p-NIK and anti-NIK antibodies, re-
spectively. The data revealed that OPN stimulates NIK phos-
phorylation in these cells (panel C, lanes 1 and 2). Western blot
data were quantified by densitometric analysis, and the -fold
changes were calculated. These results demonstrated that
OPN binds with v3 integrin receptor and induces NIK
phosphorylation.
OPN Stimulates the Interaction between Phosphorylated NIK
and IKK—To delineate whether OPN plays any role in regu-
lating the interaction between phosphorylated NIK and IKK,
B16F10 cells were treated with 5 M OPN. In separate exper-
iments, cells were individually transfected with wild type NIK
or kinase-negative NIK in the presence of LipofectAMINE Plus
and then treated with OPN. Cell lysates were immunoprecipi-
tated with rabbit polyclonal anti-IKK/ antibody. Half of the
immunoprecipitated samples were analyzed by Western blot
using anti-phospho-NIK antibody, and the remaining half of
the samples were immunoblotted with anti-IKK/ antibody.
The results indicated that cells transfected with wild type NIK
followed by treatment with OPN showed maximum interaction
between phosphorylated NIK and IKK/ compared with cells
treated with OPN alone or untreated cells (Fig. 1, panel D,
lanes 1–3). Cells transfected with kinase-negative NIK sup-
pressed the OPN-induced interaction between phosphorylated
NIK and IKK/ in these cells (lane 4). All these bands were
quantified densitometrically, and the -fold changes were calcu-
lated. These results suggested that OPN enhances the interac-
tion between phosphorylated NIK and IKK/.
OPN Induces NIK Activity and NIK-dependent IKK Activity
through Phosphorylation and Degradation of IB—To ascer-
tain the role of OPN on NIK activity, the cells were treated with
5 M OPN, and the lysates were immunoprecipitated with
rabbit anti-NIK antibody. Half of the immunoprecipitated sam-
ples were incubated with IKK as substrate in kinase assay
buffer containing [-32P]ATP. The samples were resolved by
SDS-PAGE and autoradiographed. The radiolabeled, phospho-
rylated IKK-specific band was detected in OPN-treated cells
demonstrating that OPN induces NIK activity (Fig. 2, upper
panel A, lane 2). The NIK activity was not detected in the
untreated cells (lane 1). The remaining half of the immunopre-
cipitated samples were analyzed by Western blot using anti-
NIK antibody as loading control (middle panel A). A fraction of
equal volume of samples from the kinase reaction mixture was
FIG. 2. Panel A, OPN induces NIK activity. Cells were treated with 5 M OPN, cell lysates were immunoprecipitated with anti-NIK antibody,
and half of the immunoprecipitated samples were used for the kinase assay using IKK as substrate (upper panel A, lanes 1–2). The remaining half
of the immunoprecipitated samples were immunoblotted with anti-NIK antibody (middle panel A). The fraction containing an equal volume of
kinase reaction mixture was analyzed by Western blot using anti-IKK antibody (lower panel A). Panel B, OPN stimulates NIK-dependent IKK
activity. The cells were treated with 5 M OPN or transfected with wild type and kinase-negative NIK and then treated with OPN. Cell lysates
were immunoprecipitated with anti-IKK/ antibody, and half of the immunoprecipitated samples were used for the kinase assay using IB as
substrate (panel B, a). The remaining half of the immunoprecipitated samples were analyzed by Western blot using anti-IKK/ antibody (panel
B, b). The fraction containing an equal volume of kinase reaction mixture was immunoblotted with anti-IB antibody (panel B, c). The level of
expression of NIK was also analyzed by Western blot using anti-NIK antibody (panel B, d). Panel C, NIK is required for OPN-induced IB
phosphorylation and degradation. The cells were either treated with 5 M OPN or transfected with wild type or kinase-negative NIK and then
treated with OPN as described under “Experimental Procedures.” Cell lysates were analyzed by Western blot using anti-phospho-IB (pIB)
antibody (upper panel C, lanes 1–4). The same blots were reprobed with anti-IB (middle panel C) or anti-actin (lower panel C) antibody. All these
bands were analyzed densitometrically, and the -fold changes were calculated. The data shown here represent three experiments exhibiting similar
effects. IP, immunoprecipitation; IB, immunoblot.
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analyzed by Western blot using anti-IKK/ antibody as con-
trol (lower panel A). These data demonstrated that OPN in-
duces NIK activity in these cells.
To further check whether NIK plays any direct role in OPN-
induced IKK activity, cells were transfected with wild type or
kinase-negative NIK and then treated with 5 M OPN. The cell
lysates were immunoprecipitated with rabbit anti-IKK/ an-
tibody. Half of the immunoprecipitated samples were incu-
bated with IB as substrate in kinase assay buffer containing
[-32P]ATP. The samples were resolved by SDS-PAGE and
autoradiographed. Cells transfected with wild type NIK fol-
lowed by treatment with OPN showed maximum IKK activity
(Fig. 2, panel B, a, lane 3) compared with untreated cells (lane
1) or cells induced with OPN alone (lane 2). Cells transfected
with kinase-negative NIK followed by treatment with OPN
suppressed the IKK activity significantly (lane 4) indicating
that the kinase domain of NIK plays a crucial role in OPN-
induced IKK activity. The remaining half of the immunopre-
cipitated samples were analyzed by Western blot using anti-
IKK/ antibody (panel B, b, lanes 1–4). A fraction of equal
volume of samples from the kinase reaction mixture was ana-
lyzed by Western blot using anti-IB antibody (panel B, c,
lanes 1–4). The level of NIK was also analyzed by Western blot
using anti-NIK antibody (panel B, d). These results suggested
that NIK plays a significant role in OPN-induced IKK activity.
Since we showed that OPN-induced IKK activity was regu-
lated by NIK, we therefore sought to determine whether NIK
plays any role in OPN-induced phosphorylation and degradation
of IB. Accordingly cells were either treated with 5 M OPN or
transfected with wild type or kinase-negative NIK and then
treated with OPN. The level of phosphorylated IB in cell ly-
sates was detected by Western blot using anti-phospho-IB
antibody. The data demonstrated that cells transfected with wild
type NIK enhanced OPN-induced IB phosphorylation com-
pared with untreated cells (Fig. 2, upper panel C, lanes 1–3). Cells
transfected with kinase-negative NIK suppressed OPN-induced
IB phosphorylation (lane 4). The blot was reprobed with anti-
IB antibody. The low level of IB was observed in cells
treated with OPN or transfected with wild type NIK followed by
OPN treatment indicating the degradation of IB (middle panel
C, lanes 1–4). The same blots were reprobed with anti-actin
antibody as loading control (lower panel C, lanes 1–4). These data
suggested that NIK plays a crucial role in OPN-induced IB
phosphorylation and degradation.
OPN Stimulates v3 Integrin-mediated NIK-dependent
MEK-1/ERK1/2 Phosphorylations—To examine whether NIK
plays any role in OPN-induced MEK-1 and ERK1/2 phospho-
rylations, cells were treated with 5 M OPN alone, pretreated
with v3 integrin antibody and RGD/RGE peptide, or trans-
fected with wild type and kinase-negative NIK and then
treated with OPN. Cell lysates were analyzed by Western blot
using anti-phospho-MEK-1 or anti-phospho-ERK1/2 antibody.
Wild type NIK enhanced whereas kinase-negative NIK sup-
pressed the OPN-induced MEK-1 and ERK1/2 phosphoryla-
tions in these cells (Fig. 3, upper panels A and C, lanes 1–4).
The data also indicated that OPN-induced MEK-1 phosphoryl-
ation was inhibited by v3 integrin and RGD but not RGE
peptide (upper panel B, lanes 1–5). The same blots were rep-
robed with anti-MEK-1 and anti-ERK1/2 antibodies as loading
controls (lower panels A–C). These data suggested that OPN
induces v3 integrin-dependent MEK-1 and ERK1/2 phospho-
rylations through an NIK-mediated pathway.
NIK Plays a Crucial Role in OPN-induced ERK/IKK-depend-
ent NFB-DNA Binding—We have reported earlier that OPN
induces pro-MMP-2 activation through activation of NFB. In
this study, we first examined whether NIK regulates OPN-in-
duced NFB-DNA binding in B16F10 cells. Accordingly cells
were treated with 5 M OPN or transfected with wild type and
kinase-negative NIK or wild type and dn IKK and then treated
with OPN. The nuclear extracts were prepared and used for
EMSA using 32P-labeled NFB oligonucleotides. Wild type NIK
enhanced and kinase-negative NIK suppressed OPN-induced
NFB-DNA binding (Fig. 4, panel A, lanes 1–4). Similarly wild
type IKK induced and dn IKK inhibited OPN-enhanced NFB-
DNA binding (panel B, lanes 1–4). The same results were ob-
tained in cells transfected with wild type and dn IKK (data not
shown). These data suggested that OPN induces NFB-DNA
binding through NIK/IKK-mediated pathways.
FIG. 3. OPN induces v3 integrin-mediated NIK-dependent MEK-1 and ERK1/2 phosphorylations. Panels A–C, cells were transfected
with wild type and kinase-negative NIK or pretreated with anti-v3 integrin antibody or RGD/RGE peptide (GRGDSP or GRGESP) and then
stimulated with OPN. Cell lysates were analyzed by Western blot using anti-phospho-MEK-1 (upper panels A and B) or anti-phospho-ERK1/2
(upper panel C) antibody. The same blots were reprobed with anti-MEK-1 (lower panels A and B) or anti-ERK1/2 (lower panel C) antibody. The
bands were analyzed densitometrically, and the -fold changes were calculated. The data shown here represent three experiments exhibiting similar
effects. IB, immunoblot; Ab, antibody.
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To examine the effect of ERK1/2 on OPN-induced NFB-
DNA binding, cells were pretreated with two doses of PD98059
or transfected with wild type and dominant negative constructs
of ERK1 and ERK2 and then treated with OPN. The nuclear
extracts were prepared and used for EMSA. The data revealed
that overexpression of wild type ERK1 or ERK2 resulted in an
increase in OPN-induced NFB-DNA binding, whereas dn
ERK1 or ERK2 reduced the OPN-induced NFB-DNA binding
(Fig. 4, panel E, lanes 1–6). PD98059, an MEK-1 inhibitor,
suppressed OPN-induced NFB-DNA binding (panel C, lanes
1–4). To ascertain whether OPN-induced ERK-mediated
NFB-DNA binding is NIK-dependent, cells were transfected
with wild type and kinase-negative NIK followed by treatment
with PD98059 and then stimulated with OPN. The OPN-en-
hanced NFB-DNA binding caused by overexpression of wild
type NIK was also suppressed by PD98059 (panel D, lanes
1–4). These results demonstrated that OPN induces NFB-
DNA binding through an NIK/ERK1/2-mediated pathway. To
determine whether the band obtained by EMSA was indeed
NFB, the nuclear extracts were incubated with anti-p65 an-
tibody and then analyzed by EMSA. The results showed the
shift of the NFB-specific band to a higher molecular weight
when the nuclear extracts were treated with anti-p65 antibody,
suggesting that the OPN-activated complex consists of the p65
subunit in these cells (panel F, lanes 1 and 2).
OPN Induces NIK-dependent ERK/IKK-mediated NFB
Transactivation—To further investigate whether NIK regu-
lates ERK/IKK-dependent OPN-induced NFB transcriptional
activity, a luciferase reporter gene assay was performed. Cells
were transiently transfected with NFB luciferase reporter
construct (pNFB-Luc) and then treated with OPN (5 M). In
separate experiments, cells were individually transfected with
wild type and kinase-negative NIK, the super-repressor form of
IB, wild type IKK/ and dn IKK/, or wild type ERK1/2
and dn ERK1/2 along with pNFB-Luc and then treated with
OPN (5 M). The transfection efficiency was normalized by
cotransfecting the cells with pRL vector. Changes in luciferase
activity with respect to control were calculated. The -fold
changes were calculated, and the results are expressed as the
means  S.E. of three determination. The values were also
analyzed by Student’s t test (p  0.001). The data showed that
wild type NIK enhanced but kinase-negative NIK or the super-
repressor form of IB suppressed OPN-induced NFB activity
in these cells (Fig. 5, panel A). Wild type IKK and especially
IKK enhanced OPN-induced NFB activity (panel B). Both dn
IKK and IKK suppressed OPN-induced NFB activity (panel
B). Similarly wt ERK1 and wt ERK2 enhanced whereas dn
ERK1 and dn ERK2 suppressed OPN-induced NFB activity
(panel C). These data further suggested that NIK regulates
OPN-induced ERK/IKK-dependent NFB activation.
OPN Stimulates v3 Integrin-mediated NIK- and ERK/IKK-
dependent Pro-MMP-9 Activation—To examine the effect of
OPN on pro-MMP-9 activation, the B16F10 cells were treated
with increasing concentrations of OPN (0–10 M). The condi-
tioned media were collected, and the gelatinolytic activity of
MMP-9 was detected by zymography. Increased levels of
MMP-9 expression and activation (92-kDa pro- and 86-kDa
active forms) were observed when cells were treated with two
FIG. 4. Panels A and B, OPN induces NIK/IKK-dependent NFB-DNA binding. Cells were treated with 5 M OPN. In other experiments, cells
were individually transfected with wild type and kinase-negative NIK or wild type and dn IKK and then treated with OPN. The nuclear extracts
were prepared and analyzed by EMSA. Panels C–E, ERK1/2 is involved in OPN-induced NIK-mediated NFB-DNA binding. Cells were either
pretreated with PD98059 or transfected with wild type and kinase-negative NIK, treated with PD98059, and then treated with OPN. In other
experiments, cells were transfected with wt and dn ERK1 and ERK2 and then treated with OPN. The nuclear extracts were analyzed by EMSA.
Panel F, supershift assay. The nuclear extracts from OPN-treated cells were incubated with anti-p65 antibody and analyzed by EMSA. The results
shown in A–F represent three experiments exhibiting similar effects. SS, supershift; Ab, antibody.
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different concentrations of OPN (Fig. 6, upper panel A, lanes 2
and 3). Almost no pro- and active MMP-9-specific bands were
detected in the untreated cells (lane 1). The levels of pro- and
active MMP-9 expression (gelatinolytic activity) were quanti-
fied densitometrically and analyzed statistically. As compared
with controls, there were about 3- and 5-fold increases in
MMP-9 activation when the cells were treated with 5 and 10 M
OPN, respectively (lower panel A).
To check whether v3 integrin or RGD peptide is involved in
OPN-induced pro-MMP-9 activation, cells were pretreated with
anti-v3 integrin antibody, GRGDSP, or GRGESP and then
treated with 5 M OPN. The conditioned media were collected,
and the levels of pro- and active MMP-9 were detected by
Western blot using anti-MMP-9 antibody. The level of OPN-
induced MMP-9 activation (Fig. 6, upper panel B, lane 2) was
reduced significantly when cells were individually treated with
anti-v3 integrin antibody (lane 3) or with GRGDSP peptide
(lane 4) but not with GRGESP peptide (lane 5). No detectable
level of MMP-9 was observed in OPN-untreated cells (lane 1).
The intensities of the MMP-9-specific bands were quantified
densitometrically and analyzed statistically (lower panel B).
These data suggested that v3 integrin and RGD peptide play
an important role in OPN-induced MMP-9 activation.
To investigate the role of NIK, IKK, or ERK1/2 in OPN-
induced MMP-9 activation, cells were individually transfected
with wild type NIK, kinase-negative NIK, the super-repressor
form of IB, wild type and dn IKK and IKK, or wild type
and dn ERK1/2 and then treated with 5 M OPN. The level of
MMP-9 was detected by zymography as described above. The
results indicated that wild type NIK enhanced whereas kinase-
negative NIK or the super-repressor form of IB suppressed
the OPN-induced MMP-9 activation (Fig. 6, upper panel C,
lanes 2–5). Wild type IKK enhanced but dn IKK suppressed
OPN-induced MMP-9 activation (upper panel D, lanes 2–4). No
MMP-9 was detected in OPN-untreated cells (panels C and D,
lane 1). Similar results were obtained in cells transfected with
IKK (data not shown). These bands were quantified densito-
metrically and analyzed statistically (lower panels of panels C
and D). Similarly wild type ERK1/2 enhanced and dn ERK1/2
inhibited OPN-induced pro-MMP-9 activation (data not
FIG. 5. Panels A and B, OPN enhances NFB transactivation through an NIK/IKK-mediated pathway. Cells were transiently transfected with
luciferase reporter construct (pNFB-Luc). In other experiments, cells were individually transfected with wild type and kinase-negative NIK, wild
type and dn IKK/, or the super-repressor form of IB along with pNFB-Luc. The transfected cells were treated with 5 M OPN. Cell lysates
were used to measure the luciferase activity. The values were normalized to Renilla luciferase activity. Panel C, ERK1/2 is required in
OPN-induced NFB transactivation. Cells were transfected with wild type and dn ERK1 and ERK2 along with pNFB-Luc. The transfected cells
were treated with 5 M OPN. Cell lysates were used to measure the luciferase activity. The values were normalized to Renilla luciferase activity.
The -fold changes were calculated, and means  S.E. of triplicate determinations are plotted. The values were also analyzed by Student’s t test
(*, p  0.001). sup. rep., super-repressor.
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shown). These results demonstrated that NIK regulates OPN-
induced pro-MMP-9 activation through ERK/IKK-mediated
pathways in these cells.
OPN Induces NIK-dependent IKK- and ERK1/2-mediated
uPA Secretion and uPA-dependent Pro-MMP-9 Activation—We
first examined whether NIK, IKK, and ERK1/2 are involved in
OPN-induced uPA secretion in B16F10 cells. Accordingly cells
were either treated with various concentrations of OPN (0–5
M) or transfected with wild type NIK, kinase-negative NIK,
wild type and dn IKK/, wild type ERK1/2, or dn ERK1/2 and
then treated with OPN. The cell lysates were analyzed by
Western blot using rabbit polyclonal anti-uPA antibody. The
data showed that OPN-induced uPA secretion was enhanced
when cells were transfected with wild type NIK and suppressed
when transfected with kinase-negative NIK (Fig. 7, upper
panel A, lanes 1–5, and upper panel B, lanes 1–4). Wild type
ERK1/2 stimulated and dn ERK1/2 blocked OPN-induced uPA
secretion (upper panel C, lanes 1–6). Similarly wild type
IKK/ enhanced and dn IKK/ suppressed OPN-induced
uPA secretion (data not shown). All these blots were reprobed
with anti-actin antibody (lower panels A–C), bands were quan-
tified by densitometric analysis, and the -fold changes were
calculated (panels A–C). These data suggested that OPN in-
duces NIK-dependent uPA secretion through ERK/IKK-medi-
ated pathways.
To examine whether uPA plays any role in OPN-induced
MMP-9 activation, the cells were pretreated with anti-uPA anti-
body and then treated with OPN (5 M). The level of MMP-9 was
detected by zymography and Western blot analysis. The results
indicated that uPA antibody suppressed the OPN-induced
MMP-9 activation as shown by zymography (Fig. 7, panel D,
lanes 1–3) and Western blot (panel E, lanes 1–3), indicating that
uPA is involved in OPN-induced MMP-9 activation.
uPA and MMP-9 Play Crucial Roles in OPN-induced NIK-
dependent IKK-mediated Cell Migration and Chemoinvasion—
Because NIK in the presence of OPN regulates ERK- and
IKK-dependent NFB-mediated uPA secretion and uPA-regu-
lated pro-MMP-9 activation, we therefore sought to determine
whether these signaling molecules play any role in OPN-in-
duced cell migration and chemoinvasion. Accordingly cells were
FIG. 6. Panel A, OPN induces pro-MMP-9 activity as shown by zymography. Cells were treated in the absence or presence of OPN (0–10 M).
The conditioned media were collected, and MMP-9 activity was analyzed by gelatin zymography. The arrows indicate both 92-kDa (pro-) and
86-kDa (active) MMP-9-specific bands (upper panel A, lanes 1–3). Panel B, OPN induces v3 integrin-mediated pro-MMP-9 activation. Cells were
pretreated with anti-v3 integrin antibody (20 g/ml) or GRGDSP or GRGESP peptide (10 M) and then treated with 5 M OPN. The levels of pro-
and active MMP-9 in the conditioned media were detected by Western blot using anti-MMP-9 antibody (upper panel B, lanes 1–5). Panels C and
D, OPN stimulates NIK/IKK-dependent pro-MMP-9 activation. Cells were individually transfected with wild type and kinase-negative NIK, wild
type and dn IKK, or the super-repressor form of IB and then treated with 5 M OPN. The conditioned media were collected, and MMP-9 activity
was analyzed by gelatin zymography (upper panels C and D, lanes 1–5, lanes 1–4). All these bands were quantified by densitometry and are
represented in the form of a bar graph (lower panels A–D). The data shown here represent three experiments exhibiting similar effects. sup. rep.,
super-repressor; Ab, antibody; IB, immunoblot.
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treated with anti-MMP-9 or anti-uPA antibody or transfected
with wild type NIK, kinase-negative NIK, the super-repressor
form of IB, or wild type and dn IKK and IKK and then
used for migration or chemoinvasion assay. OPN (5 M) was
used in the upper chamber. The data indicated that anti-
MMP-9 or anti-uPA antibody suppressed the OPN-induced cell
migration (Fig. 8, panel A) and chemoinvasion (panel B). Wild
type NIK enhanced whereas kinase-negative NIK or the super-
repressor form of IB suppressed the OPN-induced cell mi-
gration (panel A) and chemoinvasion (panel B). Similarly wild
type IKK and IKK stimulated and dn IKK and IKK in-
hibited the OPN-induced cell migration (panel C) and invasion
(panel D). These data demonstrated that OPN induces uPA-
and MMP-9-dependent cell migration and chemoinvasion
through NIK/IKK/NFB-mediated pathways.
ERK1/2 Plays Critical Roles in OPN-induced NIK-regulated
Cell Migration—To examine the role of ERK1/2 in OPN-in-
duced NIK-dependent cell migration, the cells were individu-
ally pretreated with PD98059, an MEK-1 inhibitor, or trans-
fected with wild type NIK and kinase-negative NIK and then
treated with PD98059. In separate experiments, cells were
transfected with wild type ERK1/2 or dn ERK1/2. These trans-
fected or treated cells were used for the migration assay. The
data indicated that PD98059 suppressed OPN-induced cell mi-
gration in the absence or presence of NIK (Fig. 9, panel D).
Similarly wild type ERK1 and wild type ERK2 enhanced and
dn ERK1 and dn ERK2 inhibited OPN-induced cell migration
(panel E). These data demonstrated that ERK1/2 plays an
important role in OPN-induced NIK-dependent cell migration.
Both MMP-2 and MMP-9 Play Important Roles in OPN-
induced Cell Migration and Chemoinvasion—We have reported
earlier that OPN induces pro-MMP-2 activation, which ulti-
mately regulates cell motility, invasiveness, and tumor growth
(20). In this study, we showed that OPN stimulates NIK-de-
pendent uPA secretion and uPA-regulated pro-MMP-9 activa-
tion. Therefore, we sought to determine whether both OPN-
induced pro-MMP-2 and pro-MMP-9 activations exert any
independent roles in regulating OPN-induced cell migration
and chemoinvasion. Accordingly cells were pretreated with ei-
ther anti-MMP-2 antibody or anti-MMP-9 antibody alone or a
mixture of both. These cells were used for a migration or
invasion assay. The data indicated that MMP-2 or MMP-9
antibody suppressed OPN-induced cell migration and chemo-
invasion (Fig. 9, panels A and B). Pretreatment of cells with a
mixture of anti-MMP-2 and anti-MMP-9 antibodies had an
additive effect and hence drastically reduced OPN-induced cell
migration and chemoinvasion (panels A and B).
To ascertain whether there is any cross-talk between OPN-
induced pro-MMP-2 and pro-MMP-9 activations, cells were
pretreated with two different concentrations of anti-MMP-2
antibody followed by treatment with OPN. The conditioned
media were collected, and the level of MMP-9 was detected by
Western blot analysis using anti-MMP-9 antibody. The data
showed that OPN-induced MMP-9 activation was unaffected
when cells were pretreated with anti-MMP-2 antibody (Fig. 9,
panel C, lanes 1–4). These data clearly indicated that OPN-
induced activations of MMP-2 and MMP-9 occurred through
two distinct signaling mechanisms, and both played independ-
ent roles in regulating cell migration and chemoinvasion in
B16F10 cells.
OPN Induces Pro-MMP-9 Activation in Tumor of Nude
Mice—The in vitro data prompted us to examine whether
FIG. 7. Panels A–C, OPN stimulates NIK- and ERK1/2-dependent uPA secretion. The cells were treated with OPN (0–5 M). In separate
experiments, cells were transfected with wild type and kinase-negative NIK or wild type and dn ERK1 and ERK2 and then treated with OPN. The
level of uPA in the cell lysates was detected by Western blot using anti-uPA antibody. The arrow indicates the uPA-specific band (upper panels
A–C). The same blots were reprobed with anti-actin antibody as loading control (lower panels A–C). Panels D and E, uPA is required in
OPN-induced pro-MMP-9 activation. Cells were pretreated with anti-uPA antibody (25 g/ml) and then treated with 5 M OPN. The conditioned
media was collected, and the MMP-9 activities were analyzed by zymography (panel D, lanes 1–3) and by Western blot (panel E, lanes 1–3). The
arrows indicate both 92- and 86-kDa MMP-9-specific bands. The results shown here represent three experiments exhibiting similar effects. IB,
immunoblot; Ab, antibody.
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OPN plays any role in MMP-9 activation in tumor of nude
mice. Accordingly B16F10 cells were treated with OPN (10
M) and were injected subcutaneously into the flanks of nude
mice. Fig. 10, panel A, shows typical photographs of tumors
grown in 4-week-old nude mice (a and b). After 4 weeks, the
mice were killed, and tumor weights were measured. The
weights of the OPN-induced tumors were increased at least
3-fold compared with the tumors of the non-OPN-injected
mice (Table I). Four mice were used in each set of experi-
ments. The changes in tumor weights were analyzed statis-
tically by Student’s t test (p  0.002). These data are consist-
ent with our previous data.
To examine the levels of pro- and active MMP-9 in tumors,
the samples were lysed, and MMP-9 expression was analyzed
by zymography (Fig. 10, panel B). The levels of both pro- and
active MMP-9 in the tumors produced by OPN (10 M) were
significantly higher (lane 2) compared with the levels of MMP-9
in the tumors of the non-OPN-injected mice (lane 1). The levels
of MMP-9 in tumors were further confirmed by Western blot
analysis (panel C). Both pro- and active MMP-9 expressions
were higher in the tumors produced by OPN (panel C), and
these are corroborated by the zymography data (panel B).
These data demonstrated that OPN induces pro-MMP-9 acti-
vation in tumor of nude mice, and it correlates with tumor
growth in nude mice.
DISCUSSION
In this study, we investigated whether OPN regulates pro-
MMP-9 activation and MMP-9-dependent cell motility, inva-
siveness, and tumor growth. Moreover we examined whether
any upstream kinase such as NIK is involved in OPN-induced
NFB activation, NFB-mediated uPA secretion, pro-MMP-9
activation, and cell motility through activation of MAPK/IKK
in B16F10 cells. We showed that OPN induced phosphorylation
and activation of NIK and enhanced the interaction between
phosphorylated NIK and IKK/ in these cells. The data re-
vealed that OPN induced NIK- and IKK-dependent NFB ac-
tivation through phosphorylation and degradation of IB.
Moreover NIK in the presence of OPN enhanced MEK-1 and
ERK1/2 phosphorylations and MEK/ERK-dependent NFB ac-
tivation. OPN induced NIK-dependent ERK/IKK-mediated
uPA secretion, uPA-dependent pro-MMP-9 activation, cell mi-
gration, and chemoinvasion. OPN induced the pro-MMP-9 ac-
tivation in tumor of nude mice. These data demonstrated that
FIG. 8. Panels A–D, NIK and IKK/ are involved in OPN-stimulated uPA and MMP-9-dependent cell migration and chemoinva-
sion. The migration assay was conducted either by using untreated cells (5  106cells/well) or cells pretreated with anti-MMP-9 antibody (25
g/ml) or anti-uPA antibody (25 g/ml). In separate experiments, cells were transfected with wild type and kinase-negative NIK, wild type and dn
IKK and IKK, or the super-repressor form of IB. The purified human OPN (5 M) was added in the upper chamber. The treated or transfected
cells were used for migration assays. Note that OPN-induced cell migration was blocked by anti-MMP-9 antibody, anti-uPA antibody, kinase-
negative NIK, and dn IKK/ and enhanced by wild type NIK and wild type IKK/ (panels A and C). The same results were obtained in the
chemoinvasion assay (panels B and D). The results are expressed as the means  S.E. of three determinations. Ab, antibody; sup. rep.,
super-repressor.
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OPN induces NIK-dependent cell motility, tumor growth,
NFB-mediated uPA secretion, and uPA-regulated pro-MMP-9
activation by activating ERK/IKK signaling pathways.
Recent studies have demonstrated that mitogen-activated
protein kinase kinase kinases including NIK and MEK kinases
1–3 are involved in the activation of IKK complex (38–40).
Kouba et al. (41) have shown that NIK regulates NFB activa-
tion pathways in epidermal keratinocytes. Thus we examined
whether NIK has any effect in OPN-induced NFB activation
in B16F10 cells. The data showed that OPN stimulated NIK
phosphorylation and its kinase activity in these cells. Pretreat-
ment of cells with anti-v3 integrin antibody or RGD but not
RGE peptide inhibited OPN-induced NIK phosphorylation in-
dicating that v3 integrin is involved in this process. Previous
data has also suggested that NIK strongly interacts with both
IKK and - (42, 43). NIK also interacts with TRAF proteins
including TRAF-3 as shown by yeast two-hybrid systems (44).
Our data revealed that OPN enhances the interaction between
phosphorylated NIK and IKK/ in B16F10 cells. Previous
studies have also indicated that IKK activation alone could not
account for the total NFB activity in HS294T cells (45). Foehr
et al. (17) have recently demonstrated that NIK regulates dif-
ferentiation of PC-12 cells through MEK/ERK pathways. These
results prompted us to investigate whether OPN regulates
NIK-dependent NFB activation through the MAPK pathway
in B16F10 cells. Our data indicated that transient overexpres-
FIG. 9. Panels A and B, both MMP-2 and MMP-9 play important roles in OPN-induced cell migration and chemoinvasion. The migration assay
was performed either by using untreated cells or cells pretreated with anti-MMP-2 antibody (25 g/ml) or anti-MMP-9 antibody (25 g/ml) or a
combination of both. The purified human OPN was added to the upper chamber. These cells were used for migration assays (panel A). The same
results were obtained in the invasion assay (panel B). Panel C, OPN-induced pro-MMP-9 activation is distinct from pro-MMP-2 activation. Cells
were pretreated with anti-MMP-2 antibody (0–50 g/ml) and then treated with 5 M OPN. The level of MMP-9 was detected by Western blot using
anti-MMP-9 antibody (panel C, lanes 1–4). Note that OPN-induced MMP-9 activation is unaffected by anti-MMP-2 antibody. Panels D and E,
ERK1/2 is involved in OPN-stimulated NIK-dependent cell migration. Cells were either pretreated with PD98059 or transfected with wild type or
kinase-negative NIK and then treated with PD98059. In separate experiments, cells were transfected with wild type and dn ERK1 and ERK2.
These treated or transfected cells were used for the cell migration assay (panels D and E). The results are expressed as the means  S.E. of three
determinations. Ab, antibody.
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sion of wild type NIK up-regulates OPN-induced MEK and
ERK1/2 phosphorylations, whereas kinase-negative NIK abro-
gated these processes. We also showed that OPN-induced NIK-
dependent MEK-1 phosphorylation was suppressed by anti-
v3 integrin blocking antibody and RGD peptide but not RGE
peptide indicating that OPN regulates NIK-mediated MAPK
activation through v3 integrin-mediated pathways.
Several reports have indicated that NFB is involved in
control of large number of cellular processes such as inflamma-
tory and immune response, developmental processes, cell
growth, and apoptosis. In addition, NFB is activated in sev-
eral pathological conditions like arthritis, inflammation,
asthma, neurodegenerative disease, heart disease, and cancers
(46). In our previous report, we have demonstrated that OPN
stimulated NFB activation by inducing the phosphatidylinosi-
tol 3-kinase/IKK activity in murine melanoma and breast can-
cer cells (21, 22). However, it was not clear whether NIK is
involved in regulation of OPN-induced NFB activation and
whether MAPK/IKK plays any role in this activation process in
B16F10 cells. In this study, we found that OPN induces NIK-
dependent IKK activity through interaction between phospho-
rylated NIK and IKK. Transfection of these cells with wild type
NIK and IKK/ but not with kinase-negative NIK or dn
IKK/ enhanced OPN-induced NFB-DNA binding and NFB
transactivation. Moreover PD98059, an MEK-1 inhibitor,
down-regulated NFB-DNA binding and NFB activation
(data not shown) in cells transfected with wild type NIK fol-
lowed by treatment with OPN. Overexpression of wild type
ERK1/2 but not dn ERK1/2 dramatically enhanced OPN-in-
duced NFB activation. These data suggested a link between
OPN-induced NIK/IKK/NFB and NIK/ERK/NFB pathways
in B16F10 cells.
Signals transduced by cell adhesion molecules play an im-
portant role in tumor cell attachment, motility, and invasion,
all of which regulate tumor metastasis. Cell-matrix interac-
tions play a major role in tissue remodeling, cell survival, and
tumorigenesis. OPN, an ECM protein, plays a significant role
in cell adhesion, migration, and metastasis. The overexpression
of OPN is linked with various cancers and their metastatic
potentials (8). MMPs are a family of Zn2-dependent endopep-
tidases that are responsible for remodeling of the extracellular
matrix and degradation of ECM proteins. MMP-9 is known to
degrade basement membrane, which normally separates the
epithelial from the stromal compartment. Elevated levels of
MMP-9 have been reported in various cancers. Several studies
have shown the correlation between MMP-9 expression and
metastatic potential of tumor (47). MMP-9 is not only associ-
ated with invasion/metastasis but also reported to be involved
in a number of angiogenic relevant diseases such as rheuma-
toid arthritis, retinopathy, and vascular stenosis and is consid-
ered to be a therapeutic target of priority (35, 36). Kim et al.
(48, 49) have also demonstrated that MMP-9 activity but not
MMP-2 activity significantly affects tumor intravasation into
blood vessel and that uPA is required for pro-MMP-9 activa-
tion. Several other reports have indicated the correlation be-
tween uPA expression and metastatic potential and shown that
uPA plays a major role in regulating MMP activation (22, 50).
Therefore, we sought to determine whether OPN regulates uPA
secretion and whether uPA plays any role in regulation of
pro-MMP-9 activation. In this study, we showed that OPN
induces uPA secretion and uPA-dependent pro-MMP-9 activa-
tion. Pretreatment of cells with anti-v3 integrin antibody or
RGD but not RGE peptide inhibited OPN-induced pro-MMP-9
activation indicating that OPN induces pro-MMP-9 activation
through v3 integrin-mediated pathways. Overexpression of
wild type NIK and IKK/ enhanced and kinase-negative NIK,
dn IKK/, or the super-repressor form of IB suppressed the
OPN-induced pro-MMP-9 activation demonstrating that OPN
regulates pro-MMP-9 activation through NIK/IKK/NFB-me-
diated pathways. Recent data also indicated that the expres-
sion of MMP-9 is down-regulated in ERK-mutated stable trans-
fectants; this inhibits glioma invasion in vitro (51). In this
study, we examined whether MAPK, especially ERK1/2, regu-
lates OPN-induced pro-MMP-9 activation in B16F10 cells. The
results showed that overexpression of wild type ERK1/2 but not
dn ERK1/2 up-regulated OPN-induced uPA secretion leading
to the activation of pro-MMP-9 indicating that OPN induces
uPA-dependent pro-MMP-9 activation through NIK/MAPK-
mediated pathways.
Previous studies have indicated that uPA and MMP-9 ex-
pressions are inversely related to MT1-MMP expression in
esophageal carcinoma (52). It has been implicated that there
are two pathways involved in esophageal carcinogenesis, one is
involved in the MT1-MMP/MMP-2 activation pathway and the
other one is the uPA/MMP-9 activation pathway, and both
pathways are critical in regulation of cancer cell motility, in-
FIG. 10. OPN induces tumor growth
and MMP-9 activation in tumors of
nude mice. Panel A, typical photographs
of tumors in nude mice. The cells were
treated in the absence or presence of OPN
(10 M) and then injected subcutaneously
into the flanks of nude mice. a, cells with
phosphate-buffered saline; b, cells with
OPN. The results show the representative
of four mice used in each set of experi-
ments. Panels B and C, detection of active
MMP-9 in tumors of nude mice by zymog-
raphy (panel B) and Western blot (panel
C). The tumor samples were lysed, and
the levels of MMP-9 in these samples
were analyzed by zymography and West-
ern blot as described earlier. The arrows
indicate the 92- and 86-kDa MMP-9-spe-
cific bands.
TABLE I
OPN induces tumor growth in nude mice
B16F10 cells were treated with 10 M OPN for 16 h and injected into
nude mice (NMRI). The injection was performed twice a week for 4
weeks. The mice were killed, and the tumor weights were measured and
analyzed statistically by Student’s t test (p  0.002). Mice injected with
cells in phosphate-buffered saline (PBS) were used as controls.
No. nude mice Treatment Tumor weight (-fold change)
4 Control (PBS) 1.0  0.15
4 OPN (10 M) 3.2  0.17
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vasiveness, tumor growth, and angiogenesis. We have reported
earlier that OPN induces pro-MMP-2 activation through
NFB-mediated induction of MT1-MMP in murine melanoma
cells (20). However, the mechanism by which OPN regulates
uPA-dependent pro-MMP-9 activation and controls cell migra-
tion, invasion, and tumor growth are not well defined. Pretreat-
ment of cells with anti-uPA antibody suppressed OPN-induced
pro-MMP-9 activation indicating that uPA plays a crucial role
in this process. Moreover pretreatment of cells with anti-
MMP-2 antibody along with anti-MMP-9 antibody dramati-
cally suppressed the OPN-induced cell migration and chemo-
invasion, whereas pretreatment of cells with anti-MMP-2
antibody had no effect on OPN-induced pro-MMP-9 activation.
These data suggested that both MMP-2 and MMP-9 are in-
volved in OPN-induced cell migration and chemoinvasion, but
OPN-induced MMP-2 activation is distinct from MMP-9 acti-
vation. Wild type NIK, IKK/, and ERK1/2 enhanced and
kinase-negative NIK, dn IKK/, and dn ERK1/2 suppressed
OPN-induced cell migration and chemoinvasion. OPN also in-
duced the pro-MMP-9 activation in tumor of nude mice. These
data demonstrated that OPN induces NIK-regulated NFB-
mediated uPA-dependent pro-MMP-9 activation, cell motility,
and tumor growth via ERK/IKK-mediated signaling pathways.
In summary, we demonstrated for the first time that OPN
induces activation and phosphorylation of NIK through interac-
tion between IKK and phosphorylated NIK. OPN also enhances
NIK-dependent IKK/- and ERK1/2-mediated NFB activation,
uPA secretion, and pro-MMP-9 activation. Taken together, OPN
induces cell migration, tumor growth, and NIK-dependent
NFB-mediated uPA secretion and pro-MMP-9 activation by ac-
tivating IKK/ERK signaling pathways (Fig. 11). These findings
may be useful in designing novel therapeutic interventions that
block the OPN-regulated NIK-dependent IKK- and ERK1/2-me-
diated NFB activation resulting in reduction of uPA secretion
and pro-MMP-9 activation and consequent blocking of cell motil-
ity, invasiveness- and melanoma growth.
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